Frontiers in Medicine · Nov 6, 2026

From Toxicity to Ecosystem: Oncorheumatology as an Emerging Domain, a Multidisciplinary Guide for Risk Stratification and Standardized Management

By Daniela Marotto, Guido Putignano, Luigi Pirtoli et al.

Background: Onco-Rheumatology describes the interplay between systemic autoimmune rheumatic diseases (SARDs) and cancer, driven by shared inflammatory pathways and shaped by disease activity and therapeutic exposures. Although immune-related adverse events (irAEs) and long-term treatment toxicities are increasingly recognised, clinical integration and standardized management algorithms remain limited. Objective: This interdisciplinary narrative review provides an overview of the clinical and mechanistic challenges at the intersection of rheumatology and oncology, focusing on diagnosis, risk stratification and integrated patient-centred care. Methods: Targeted searches of PubMed/MEDLINE and professional repositories (EULAR, ASCO) were performed from inception to December 2025 and updated in September 2026. Peer-reviewed evidence was critically appraised and synthesized narratively. Results: Cancer risk in SARDs is increased but highly heterogeneous, ranging from a marginal excess in rheumatoid arthritis (standardised incidence ratio approximately 1.1) to an approximately 14-fold excess of non-Hodgkin lymphoma in primary Sjögren's syndrome, and its time course separates short-latency paraneoplastic associations from long-latency, activity-dependent ones. We propose that the field's defining clinical phenomena can be interpreted as outputs of a shared, self-amplifying NF-κB–STAT3 circuit that licenses myeloid-derived suppressor cells, regulatory T cells and tumour-associated macrophages, drives epithelial-to-mesenchymal transition and sustains synovial inflammation, with TGF-β acting as a context-dependent switch between tolerance, fibrosis and tumour immune exclusion. Inflammation-driven mutagenesis and clonal selection (clonal haematopoiesis; VEXAS syndrome) link the two disease states genetically, and somatic mutation of autoantigens has been proposed to explain a subset of paraneoplastic rheumatic disease. Each mechanism is graded as established, supported or hypothesised. Rheumatologic paraneoplastic syndromes may herald occult neoplasia in up to 15% of cases, and immune checkpoint inhibitors frequently induce rheumatic irAEs, often seronegative, for which classification criteria are in development. Clinical evidence for natural compounds acting on these pathways remains limited. Significant gaps remain in paediatric care and survivorship. Conclusion: Onco-Rheumatology would benefit from formal multidisciplinary frameworks, such as the proposed Group of Multidisciplinary Onco-Rheumatology (G-MORE). Standardized risk stratification tools, diagnostic pathways, rehabilitation strategies and structured long-term surveillance are key to optimizing oncologic and rheumatologic outcomes. We also propose five testable mechanistic questions and the infrastructure needed to answer them.

The paperJournal siteMechanisms

AgingResearch.News